23andMe and Genentech in deal to analyze genomic data for Parkinson's disease

6 January 2015

23andMe, the leading personal genetics company, and Genentech, a subsidiary of Swiss pharma giant Roche (ROG: SIX), have joined forces to generate whole genome sequencing data for around 3,000 people in 23andMe's Parkinson's disease community. The goal of the collaboration is to identify new therapeutic targets for treating Parkinson's disease.

"We are incredibly excited to work with Genentech again, and for the potential to make true breakthroughs in therapeutic research and treatment for Parkinson's disease," said 23andMe president Andy Page, adding: "23andMe's research platform is unlike any other for fueling genomic discoveries that have the potential to help treat and solve disease. This collaboration is truly emblematic of both companies' broader vision of improving the human condition through genetic research."

Deal could earn 23andMe $60 million

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology